Limited Use of Newest Neurological Drugs Seen Across 10 Conditions

Use of newly approved neurological therapies among privately insured patients remains low. For 10 of 11 neurological conditions, use of new-to-market medications (approved 2014 to 2018) was less than 20% vs. existing, guideline-supported medications, with highly variable out-of-pocket costs.

Read this Next
About UsOur ProductsCustom SolutionsHow it’s SoldOur ResultsDeliveryContact UsBlogPrivacy PolicyFAQ